Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
18 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04738487 | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) | terminated | Phase 3 | 1,264 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT05298423 | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)(KEYVIBE-006) | completed | Phase 3 | 610 |
| Merck Sharp & Dohme LLCINDUSTRY |
| 25 |
| Aug 28, 2026 |
| clinicaltrials |
| NCT04947605 | Epidemiological Landscape of Cervical Cancer in Latin America(EVITA LATAM) | active not recruiting | — | 524 | Latin American Cooperative Oncology GroupOTHER | 4 | Aug 27, 2026 | clinicaltrials |
| NCT04158258 | A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | completed | — | 2,907 | Hoffmann-La RocheINDUSTRY | 10 | Aug 17, 2026 | clinicaltrials |
| NCT07225530 | Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)((iSTAR)) | recruiting | N/A | 600 | Columbia UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05556772 | Optimizing Screening for Cervical Cancer Among Women Living With HIV in the Dominican Republic | active not recruiting | N/A | 619 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05091437 | DOuBLED - Doubling Outcomes by Lung Cancer Early Diagnosis(DOuBLED) | completed | — | 562 | AstraZenecaINDUSTRY | 8 | Sep 24, 2025 | clinicaltrials |
| NCT06131424 | NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients(iRetroBC) | completed | — | 1,151 | AstraZenecaINDUSTRY | 13 | Sep 18, 2025 | clinicaltrials |
| NCT04964908 | Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia(CREEK) | completed | — | 1,088 | AstraZenecaINDUSTRY | 17 | Feb 20, 2024 | clinicaltrials |
| NCT04742192 | Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer(EARLY-EGFR) | completed | — | 601 | AstraZenecaINDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT02594371 | Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer | completed | Phase 3 | 402 | Athenex, Inc.INDUSTRY | 10 | Aug 3, 2022 | clinicaltrials |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | completed | Phase 3 | 2,185 | Hoffmann-La RocheINDUSTRY | 43 | Apr 4, 2022 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT02788214 | Helicobacter Pylori Genome Project (HpGP) | terminated | — | 1,000 | National Cancer Institute (NCI)NIH | 53 | Dec 19, 2020 | clinicaltrials |
| NCT03725475 | A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients(KINDLE) | completed | — | 3,111 | AstraZenecaINDUSTRY | 10 | Oct 5, 2020 | clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT02796066 | TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris | withdrawn | Phase 2 | 0 | Thesan Pharmaceuticals, Inc.INDUSTRY | 3 | Apr 26, 2017 | clinicaltrials |
Data updated 12 days agoSource updated unknownsource: clinicaltrials